246 results on '"Trautmann, Michael"'
Search Results
2. Autorenprofile
3. Teil 1: Starkes Ich
4. Endnoten
5. Teil 2: Starkes Wir
6. Teil 3: Starke Gesellschaft
7. Nachwort von Stephan A. Jansen
8. Danke
9. Kommunikation: Je emotionaler das Thema,desto synchroner der Kanal
10. Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials
11. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data
12. Separation of platinum and ruthenium by a sulphoxide modified polystyrene resin in laboratory column systems
13. Five-Year Efficacy and Safety Data of Exenatide Once Weekly: Long-term Results From the DURATION-1 Randomized Clinical Trial
14. Preparation, characterisation and properties of sulphoxide modified polystyrene resins for solid-phase extraction of PtIV, RuIII and RuIV from hydrochloric acid
15. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
16. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
17. Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years
18. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
19. ON THE WAY TO NEW WORK
20. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
21. Die Fernsehwerbung in Deutschland: Status und Perspektiven
22. Zahlen mit Signalwirkung
23. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
24. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
25. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
26. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study
27. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
28. Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
29. DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
30. Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study
31. Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes
32. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
33. Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
34. Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
35. The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
36. Safety and Effects of a Once-Weekly, Long-Acting Release Formulation of Exenatide over 15 Weeks in Patients with Type 2 Diabetes: 487-P
37. Effects of Exenatide on Gastric Emptying and Postprandial Glucose in Type 2 Diabetes: 116-OR
38. Safety and Efficacy of Exenatide in Patients with Type 2 Diabetes Mellitus Using Thiazolidenediones with or without Metformin: 117-OR
39. Somatostatin analog Sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors
40. Hyperinsulinemic Hypoglycemia with Nesidioblastosis after Gastric-Bypass Surgery
41. Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
42. Use of Insulin Lispro in Continuous Subcutaneous Insulin Infusion Treatment: Results of a multicenter trial
43. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
44. Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
45. 53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study
46. 1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
47. 1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203
48. Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post‐hoc analysis of the DURATION‐3 study
49. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
50. Mealtime Treatment With Insulin Analog Improves Postprandial Hyperglycemia and Hypoglycemia in Patients With Non-Insulin-Dependent Diabetes Mellitus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.